Therapy Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name	Taletrectinib
Synonyms
Therapy Description	Ibtrozi (taletrectinib) is an inhibitor of NTRK1/2/3 and ROS1 fusion proteins, which blocks downstream signaling and may lead to inhibition of tumor cell growth (PMID: 32591465). Ibtrozi (taletrectinib) is FDA-approved for use in patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (FDA.gov).

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 1 of 1 entries

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
Taletrectinib	Ibtrozi	DS6051b\|DS-6051B\|DS-6051\|AB-106	ROS1 Inhibitor 23 Trk Receptor Inhibitor (Pan) 33	Ibtrozi (taletrectinib) is an inhibitor of NTRK1/2/3 and ROS1 fusion proteins, which blocks downstream signaling and may lead to inhibition of tumor cell growth (PMID: 32591465). Ibtrozi (taletrectinib) is FDA-approved for use in patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (FDA.gov).

Showing 1 to 1 of 1 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 7 of 7 entries

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
ROS1 fusion	lung non-small cell carcinoma	sensitive	Taletrectinib	FDA approved	Actionable	In a Phase II trial (TRUST-I) that supported FDA approval, Ibtrozi (taletrectinib) treatment resulted in a 90.6% (96/106) overall response rate (ORR) and 95.3% disease control rate (DCR) in TKI-naive non-small cell lung cancer patients with ROS1 fusions and 51.5% (34/66) ORR and 83.3% DCR in pretreated patients, intracranial ORR of 87.5% (7/8) and DCR of 100% in patients with baseline brain lesions, and partial responses in 8 of 12 patients with secondary ROS1 G2032R mutations (PMID: 38822758; NCT04395677).	38822758 detail...
ROS1 fusion	lung non-small cell carcinoma	sensitive	Taletrectinib	FDA approved	Actionable	In a Phase II trial (TRUST-II) that supported FDA approval, Ibtrozi (taletrectinib) treatment demonstrated safety in ROS1 fusion-positive non-small cell lung cancer patients and resulted in a confirmed investigator-assessed objective response rate (cORRinv) of 94% (17/18) and a disease control rate (DCR) of 100% in the treatment-naive cohort and a cORRinv of 55% (12/22) and DCR of 91% in the previously treated cohort (Ann Oncol (2023) 34 (suppl_2):S788-S789; NCT04919811).	detail... detail...
ROS1 fusion	lung non-small cell carcinoma	sensitive	Taletrectinib	Phase II	Actionable	In a combined analysis of 2 Phase II trials (TRUST-I, TRUST-II), Ibtrozi (taletrectinib) treatment was safe and resulted in a confirmed objective response rate (cORR) of 88.8%, a median duration of response (mDOR) of 44.2 mo, and a median progression-free survival of 45.6 mo in TKI-naive, ROS1 fusion-positive non-small cell lung cancer patients (n=160), and a cORR of 55.8%, mDOR of 16.6 mo, and mPFS of 9.7 mo in TKI-pretreated patients (n=113) (PMID: 40179330; NCT04919811, NCT04395677).	40179330
ROS1 fusion	lung non-small cell carcinoma	sensitive	Taletrectinib	Phase I	Actionable	In a Phase I trial, Ibtrozi (taletrectinib) was well-tolerated and demonstrated some preliminary efficacy in patients with advanced solid tumors, including a partial response in a patient with non-small cell lung cancer liver metastases harboring a ROS1 fusion (Cancer Res 2016;76(14 Suppl):Abstract nr CT024; NCT02279433).	detail...
ROS1 rearrange	lung non-small cell carcinoma	predicted - sensitive	Taletrectinib	Phase I	Actionable	In a Phase I trial, Ibtrozi (taletrectinib) demonstrated manageable toxicity, resulted in an objective response rate of 33.3% (2/6) in patients with advanced non-small cell lung cancer harboring ROS1 rearrangements (PMID: 32591465).	32591465
ROS1 fusion ROS1 G2032R	lung non-small cell carcinoma	predicted - sensitive	Taletrectinib	Case Reports/Case Series	Actionable	In a Phase II trial (TRUST-I), Ibtrozi (taletrectinib) treatment resulted in an objective response rate of 66.7% (8/12, all partial responses) in patients with non-small cell lung cancer harboring ROS1 fusions with secondary ROS1 G2032R mutations (PMID: 38822758; NCT04395677).	38822758
EML4 - ALK	Advanced Solid Tumor	sensitive	Taletrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing EML4-ALK were sensitive to treatment with Ibtrozi (taletrectinib) in culture, demonstrating cell growth inhibition (PMID: 31399568).	31399568

Showing 1 to 7 of 7 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 3 of 3 entries

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT02279433	Phase I	Taletrectinib	A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b	Completed	USA	0
NCT04919811	Phase II	Taletrectinib	Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC (TRUST-II)	Recruiting	USA \| POL \| ITA \| FRA \| ESP \| CAN	3
NCT06214793	Phase II	Taletrectinib	Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)	Suspended	USA	0

Showing 1 to 3 of 3 entries

Filter rows:

Additional content available in CKB BOOST